{"id":251004,"date":"2025-01-06T00:00:00","date_gmt":"2025-01-06T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidim0083-biopharma-psoriasis-epidemiology-europe\/"},"modified":"2026-03-31T10:27:21","modified_gmt":"2026-03-31T10:27:21","slug":"epidim0083-biopharma-psoriasis-epidemiology-europe","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidim0083-biopharma-psoriasis-epidemiology-europe\/","title":{"rendered":"Psoriasis &#8211; Epidemiology &#8211; Europe"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of psoriasis (<abbr title=\"psoriasis\">PsO<\/abbr>) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of <abbr title=\"psoriasis\">PsO<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the mature pharmaceutical markets (United States, European countries, and Japan) and 10 years for the other countries covered in this report.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"psoriasis\">PsO<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>Of all people diagnosed with <abbr title=\"psoriasis\">PsO<\/abbr>, how many in each of the developed countries are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"psoriasis\">PsO<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <span class=\"abbreviation-guard\">MS<\/span> Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts 10 <abbr title=\"psoriasis\">PsO<\/abbr> patient populations, including the following:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed 12-month prevalent cases of <abbr title=\"psoriasis\">PsO<\/abbr>.<\/li>\n<li>Diagnosed 12-month prevalent cases of mild <abbr title=\"psoriasis\">PsO<\/abbr>.<\/li>\n<li>Diagnosed 12-month prevalent cases of moderate <abbr title=\"psoriasis\">PsO<\/abbr>.<\/li>\n<li>Diagnosed 12-month prevalent cases of severe <abbr title=\"psoriasis\">PsO<\/abbr>.<\/li>\n<li>Diagnosed 12-month prevalent cases of drug-treated <abbr title=\"psoriasis\">PsO<\/abbr>.<\/li>\n<li>Diagnosed 12-month prevalent cases of plaque <abbr title=\"psoriasis\">PsO<\/abbr>.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-251004","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-psoriasis","biopharma-product-epidemiology","biopharma-geography-europe","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251004","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251004\/revisions"}],"predecessor-version":[{"id":433918,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251004\/revisions\/433918"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251004"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}